Gene-directed enzyme prodrug therapy: A current assessment

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 4, 2004, Pages 421-435

  McKeown, Stephanie R ^a   Ward, Claire ^a   Robson, Tracy ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Cancer; Gene directed enzyme prodrug therapy; Prodrugs; Suicide gene therapy

Indexed keywords

1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 4 IPOMEANOL; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ADENOVIRUS VECTOR; CARBOXYLESTERASE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B1; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; CYTOCHROME P450 4B1; CYTOCHROME REDUCTASE; CYTOSINE DEAMINASE; DOXIFLURIDINE; DOXORUBICIN; DRUG METABOLIZING ENZYME; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; HORSERADISH PEROXIDASE; IFOSFAMIDE; INDOLEACETIC ACID; IRINOTECAN; METHIONINE GAMMA LYASE; NITROREDUCTASE; PRODRUG; SELENOMETHIONINE; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; TIRAPAZAMINE; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CYTOTOXICITY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; EPILEPSY; GENE DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LIVER METASTASIS; LIVER TOXICITY; MELANOMA; MESOTHELIOMA; NECROSIS; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; REVIEW;

ANIMALS; BYSTANDER EFFECT; CLINICAL TRIALS; ENZYMES; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; NEOPLASMS; PRODRUGS;

EID: 4444318140     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (158)

1. Robson T, Hirst DG: Transcriptional targeting in cancer gene therapy. J Biomed Biotechnol (2003) 2003(2):110-137.
2. Koshikawa N, Takenaga K, Tagawa M, Sakiyama S: Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res (2000) 60(11):2936-2941.
3. Shibata T, Giaccia AJ, Brown JM: Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia (2002) 4(1):40-48.
4. Latham JP, Searle PF, Mautner V, James ND: Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector. Cancer Res (2000) 60(2):334-341.
5. Wu L, Matherly J, Smallwood A, Adams JY, Billick E, Belldegrun A, Carey M: Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther (2001) 8(18):1416-1426.
6. Kawashita Y, Ohtsuru A, Kaneda Y, Nagayama Y, Kawazoe Y, Eguchi S, Kuroda H, Fujioka H, Ito M, Kanematsu T, Yamashita S: Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation. Hum Gene Ther (1999) 10(9):1509-1519.
7. Worthington J, Robson T, Murray M, O'Rourke M, Keilty G, Hirst DG: Modification of vascular tone using iNOS under the control of a radiation-inducible promoter. Gene Ther (2000) 7(13):1126-1131.
8. Worthington J, Robson T, O'Keeffe M, Hirst DG: Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: A novel suicide gene therapy. Gene Ther (2002) 9(4):263-269.
9. Worthington J, McCarthy HO, Barrett E, Adams C, Robson T, Hirst DG: Use of the radiation-inducible WAF-1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment. J Gene Med (2004) 6(6):673-680.
10. Denny WA: Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J Biomed Biotechnol (2003) 2003(1):48-70.
11. Patterson LH, McKeown SR: AQ4N: A new approach to hypoxia-activated cancer chemotherapy. Br J Cancer (2000) 83(12):1589-1593.
12. Brown JM: Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies. Mol Med Today (2000) 6(4):157-162.
13. McKeown SR, Hejmadi MV, McIntyre IA, McAleer JJ, Patterson LH: AQ4N: An alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer (1995) 72(1):76-81.
14. McKeown SR, Friery OP, McIntyre IA, Hejmadi MV, Patterson LH, Hirst DG: Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. Br J Cancer Suppl (1996) 27:S39-S42.
15. Friery OP, Gallagher R, Murray MM, Hughes CM, Galligan ES, McIntyre IA, Patterson LH, Hirst DG, McKeown SR: Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine. Br J Cancer (2000) 82(8):1469-1473.
16. Gallagher R, Hughes CM, Murray MM, Friery OP, Patterson LH, Hirst DG, McKeown SR: The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br J Cancer (2001) 85(4):625-629.
17. Brown JM, Wang LH: Tirapazamine: Laboratory data relevant to clinical activity. Anticancer Drug Des (1998) 13(6):529-539.
18. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (1996) 379(6560):88-91.
19. L. J Biol Chem (2004) 279(10):9215-9221.
20. Elion GB: The biochemistry and mechanism of action of acyclovir. J Antimicrob Chemother (1983) 12(Suppl B):9-17.
21. Mar EC, Chiou JF, Cheng YC, Huang ES: Inhibition of cellular DNA polymerase α and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J Virol (1985) 53(3):776-780.
22. Vlachaki MT, Chhikara M, Aguilar L, Zhu X, Chiu KJ, Woo S, Teh BS, Thompson TC, Butler EB, Aguilar-Cordova E: Enhanced therapeutic effect of multiple injections of HSV-tk + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model. Int J Radiat Oncol Biol Phys (2001) 51(4):1008-1017.
23. Kanazawa T, Mizukami H, Okada T, Hanazono Y, Kume A, Nishino H, Takeuchi K, Kitamura. K, Ichimura K, Ozawa K: Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Ther (2003) 10(1):51-58.
24. Jones RK, Pope IM, Kinsella AR, Watson AJ, Christmas SE: Combined suicide and granulocyte-macrophage colony-stimulating factor gene therapy induces complete tumor regression and generates antitumor immunity. Cancer Gene Ther (2000) 7(12):1519-1528.
25. Tyynela K, Sandmair AM, Turunen M, Vanninen R, Vainio P, Kauppinen R, Johansson R, Vapalahti M, Yla-Herttuala S: Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model. Cancer Gene Ther (2002) 9(11):917-924.
26. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN: The 'bystander effect': Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res (1993) 53(21):5274-5283.
27. Mesnil M, Yamasaki H: Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication. Cancer Res (2000) 60(15):3989-3999.
28. Burrows FJ, Gore M, Smiley WR, Kanemitsu MY, Jolly DJ, Read SB, Nicholas T, Kruse CA: Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells. Cancer Gene Ther (2002) 9(1):87-95.
29. Greco E, Fogar P, Basso D, Stefani AL, Navaglia F, Zambon CF, Mazza S, Gallo N, Piva MG, Scarpa A, Pedrazzoli S, Plebani M: Retrovirus-mediated herpes simplex virus thymidine kinase gene transfer in pancreatic cancer cell lines: An incomplete antitumor effect. Pancreas (2002) 25(2):e21-e29.
30. Matono S, Tanaka T, Sueyoshi S, Yamana H, Fujita H, Shirouzu K: Bystander effect in suicide gene therapy is directly proportional to the degree of gap junctional intercellular communication in esophageal cancer. Int J Oncol (2003) 23(5):1309-1315.
31. Asklund T, Appelskog IB, Ammerpohl O, Langmoen IA, Dilber MS, Aints A, Ekstrom TJ, Almqvist PM: Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene. Exp Cell Res (2003) 284(2):185-195.
32. van Dillen IJ, Mulder NH, Vaalburg W, de Vries EF, Hospers GA: Influence of the bystander effect on HSV-tk/GCV gene therapy. A review. Curr Gene Ther (2002) 2(3):307-322.
33. Adachi M, Sampath J, Lan LB, Sun D, Hargrove P, Flatley R, Tatum A, Edwards MZ, Wezeman M, Matherly L, Drake R, Schuetz J: Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing. J Biol Chem (2002) 277(41):38998-39004.
34. Parada C, Hernandez Losa J, Guinea J, Sanchez-Arevalo V, Fernandez Soria V, Alvarez-Vallina L, Sanchez-Prieto R, Ramon y Cajal S: Adenovirus E1a protein enhances the cytotoxic effects of the herpes thymidine kinase-ganciclovir system. Cancer Gene Ther (2003) 10(2):152-160.
35. Wiewrodt R, Amin K, Kiefer M, Jovanovic VP, Kapoor V, Force S, Chang M, Lanuti M, Black ME, Kaiser LR, Albelda SM: Adenovirus-mediated gene transfer of enhanced herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing. Cancer Gene Ther (2003) 10(5):353-364.
36. Miura F, Moriuchi S, Maeda M, Sano A, Maruno M, Tsanaclis AM, Marino R Jr, Glorioso JC, Yoshimine T: Sustained release of low-dose ganciclovir from a silicone formulation prolonged the survival of rats with gliosarcomas under herpes simplex virus thymidine kinase suicide gene therapy. Gene Ther (2002) 9(24):1653-1658.
37. Maeda M, Moriuchi S, Sano A, Yoshimine T: New drug delivery system for water-soluble drugs using silicone and its usefulness for local treatment: Application of GCV-silicone to GCV/HSV-tk gene therapy for brain tumor. J Control Release (2002) 84(1-2):15-25.
38. Beltinger C, Fulda S, Walczak H, Debatin KM: TRAIL enhances thymidine kinase/ganciclovir gene therapy of neuroblastoma cells. Cancer Gene Ther (2002) 9(4):372-381.
39. Kwon GY, Jeong J, Woo JK, Choi HY, Lee MJ, Ko JK, Shim YH, Kim CW: Co-expression of bfl-1 enhances host response in the herpes simplex virus-thymidine kinase/ganciclovir gene therapy system. Biochem Biophys Res Commun (2003) 303(3):756-763.
40. Sieger S, Jiang S, Kleinschmidt J, Eskerski H, Schonsiegel F, Altmann A, Mier W, Haberkorn U: Tumor-specific gene expression using regulatory elements of the glucose transporter isoform 1 gene. Cancer Gene Ther (2004) 11(1):41-51.
41. Yamazaki M, Straus FH, Messina M, Robinson BG, Takeda T, Hashizume K, DeGroot LJ: Adenovirus-mediated tumor-specific combined gene therapy using herpes simplex virus thymidine/ganciclovir system and murine interleukin-12 induces effective antitumor activity against medullary thyroid carcinoma. Cancer Gene Ther (2004) 11(1):8-15.
42. Fillat C, Carrio M, Cascante A, Sangro B: Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/ganciclovir system: Fifteen years of application. Curr Gene Ther (2003) 3(1):13-26.
43. Ciccolini J, Evrard A, Cuq P: Thymidine phosphorylase and fluoropyrimidines efficacy: A Jekyl and Hyde story. Curr Med Chem Anticancer Agents (2004) 4(2):71-81.
44. Kanai F, Lan KH, Shiratori Y, Tanaka T, Ohashi M, Okudaira T, Yoshida Y, Wakimoto H, Hamada H, Nakabayashi H, Tamaoki T, Omata M: In vivo gene therapy for α-fetoprotein-producing hapatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res (1997) 57(3):461-465.
45. Ge K, Xu L, Zheng Z, Xu D, Sun L, Liu X: Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine. Int J Cancer (1997) 71(4):675-679.
46. Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY: Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res (2002) 62(3):773-780.
47. Shirakawa T, Gardner TA, Ko SC, Bander N, Woo S, Gotoh A, Kamidono S, Chung LW, Kao C: Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model. J Urol (1999) 162(3 Pt 1):949-954.
48. Lawrence TS, Rehemtulla A, Ng EY, Wilson M, Trosko JE, Stetson PL: Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res (1998) 58(12):2588-2593.
49. Huber BE, Austin EA, Richards CA, Davis ST, Good SS: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA (1994) 91(17):8302-8306.
50. Stackhouse MA, Pederson LC, Grizzle WE, Curiel DT, Gebert J, Haack K, Vickers SM, Mayo MS, Buchsbaum DJ: Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models. Gene Ther (2000) 7(12):1019-1026.
51. Kievit E, Nyati MK, Ng E, Stegman LD, Parsels J, Ross BD, Rehemtulla A, Lawrence TS: Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res (2000) 60(23):6649-6655.
52. Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA: Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst (1998) 90(5):370-380.
53. Moriuchi S, Wolfe D, Tamura M, Yoshimine T, Miura F, Cohen JB, Glorioso JC: Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther (2002) 9(9):584-591.
54. Cao X, Huang X, Ju DW, Zhang W, Hamada H, Wang J: Enhanced antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Gene Ther (2000) 7(2):177-186.
55. Ju DW, Yang Y, Tao Q, Song WG, He L, Chen G, Gu S, Ting CC, Cao X: Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity. Gene Ther (2000) 7(19):1672-1679.
56. Adachi Y, Tamiya T, Ichikawa T, Terada K, Ono Y, Matsumoto K, Furuta T, Hamada H, Ohmoto T: Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine. Hum Gene Ther (2000) 11(1):77-89.
57. Miyagi T, Koshida K, Hori O, Konaka H, Katoh H, Kitagawa Y, Mizokami A, Egawa M, Ogawa S, Hamada H, Namiki M: Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyltransferase suicide system. J Gene Med (2003) 5(1):30-37.
58. Desaknai S, Lumniczky K, Esik O, Hamada H, Safrany G: Local tumour irradiation enhances the anti-tumour effect of a double-suicide gene therapy system in a murine glioma model. J Gene Med (2003) 5(5):377-385.
59. Hamstra DA, Rice DJ, Fahmy S, Ross BD, Rehemtulla A: Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Ther (1999) 10(12):1993-2003.
60. Kievit E, Bershad E, Ng E, Sethna P, Dev I, Lawrence TS, Rehemtulla A: Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res (1999) 59(7):1417-1421.
61. Nyati MK, Sreekumar A, Li S, Zhang M, Rynkiewicz SD, Chinnaiyan AM, Rehemtulla A, Lawrence TS: High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoter-enhancer. Cancer Res (2002) 62(8):2337-2342.
62. Wang XP, Yazawa K, Yang J, Kohn D, Fisher WE, Brunicardi FC: Specific gene expression and therapy for pancreatic cancer using the cytosine deaminase gene directed by the rat insulin promoter. J Gastrointest Surg (2004) 8(1):98-108.
63. Evrard A, Cuq P, Ciccolini J, Vian L, Cano JP: Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br J Cancer (1999) 80(11):1726-1733.
64. de Bruin M, van Capel T, Van der Born K, Kruyt FA, Fukushima M, Hoekman K, Pinedo HM, Peters GJ: Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br J Cancer (2003) 88(6):957-964.
65. Sumizawa T, Furukawa T, Haraguchi M, Yoshimura A, Takeyasu A, Ishizawa M, Yamada Y, Akiyama S: Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. J Biochem (1993) 114(1):9-14.
66. van Triest B, Pinedo HM, Blaauwgeers JL, van Diest PJ, Schoenmakers PS, Voorn DA, Smid K, Hoekman K, Hoitsma HF, Peters GJ: Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res (2000) 6(3):1063-1072.
67. Knox RJ, Friedlos F, Marchbank T, Roberts JJ: Bioactivation of CB 1954: Reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. Biochem Pharmacol (1991) 42(9):1691-1697.
68. Bridgewater JA, Springer CJ, Knox RJ, Minton NP, Michael NP, Collins MK: Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer (1995) 31A(13-14):2362-2370.
69. Weedon SJ, Green NK, McNeish IA, Gilligan MG, Mautner V, Wrighton CJ, Mountain A, Young LS, Kerr DJ, Searle PF: Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. Int J Cancer (2000) 86(6):848-854.
70. Djeha AH, Thomson TA, Leung H, Searle PF, Young LS, Kerr DJ, Harris PA, Mountain A, Wrighton CJ: Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: A well-tolerated therapy for established solid tumors. Mol Ther (2001) 3(2):233-240.
71. Palmer DH, Milner AE, Kerr DJ, Young LS: Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil. Br J Cancer (2003) 89(5):944-950.
72. Bridgewater JA, Knox RJ, Pitts JD, Collins MK, Springer CJ: The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum Gene Ther (1997) 8(6):709-717.
73. Helsby NA, Ferry DM, Patterson AV, Pullen SM, Wilson WR: 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. Br J Cancer (2004) 90(5):1084-1092.
74. Benouchan M, Do Nascimento F, Sebbah-Louriki M, Salzmann JL, Crepin M, Perret GY, Colombo BM: Bystander cell killing spreading from endothelial to tumor cells in a three-dimensional multicellular nodule model after Escherichia coli nitroreductase gene delivery. Biochem Biophys Res Commun (2003) 311(4):822-828.
75. Lipinski KS, Djeha AH, Ismail T, Mountain A, Young LS, Wrighton CJ: High-level, β-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue. Mol Ther (2001) 4(4 ):365-371.
76. Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ, McGregor F, Evans TR, Ganly I, Knox RJ, Plumb JA, Keith WN: Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene (2003) 22(3):370-380.
77. Grove JI, Lovering AL, Guise C, Race PR, Wrighton CJ, White SA, Hyde EI, Searle PF: Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. Cancer Res (2003) 63(17):5532-5537.
78. Green NK, McNeish IA, Doshi R, Searle PF, Kerr DJ, Young LS: Immune enhancement of nitroreductase-induced cytotoxicity: Studies using a bicistronic adenovirus vector. Int J Cancer (2003) 104(1):104-112.
79. Parker WB, Allan PW, Shaddix SC, Rose LM, Speegle HF, Gillespie GY, Bennett LL Jr: Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol (1998) 55(10):1673-1681.
80. Hughes BW, King SA, Allan PW, Parker WB, Sorscher EJ: Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase. J Biol Chem (1998) 273(4):2322-2328.
81. Gadi VK, Alexander SD, Kudlow JE, Allan P, Parker WB, Sorscher EJ: In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther (2000) 7(20):1738-1743.
82. Gadi VK, Alexander SD, Waud WR, Allan PW, Parker WB, Sorscher EJ: A long-acting suicide gene toxin, 6-methylpurine, inhibits slow growing tumors after a single administration. J Pharmacol Exp Ther (2003) 304(3):1280-1284.
83. Deharvengt S, Wack S, Uhring M, Aprahamian M, Hajri A: Suicide gene/prodrug therapy for pancreatic adenocarcinoma by E. coli purine nucleoside phosphorylase and 6-methyipurine 2′ -deoxyriboside. Pancreas (2004) 28(2):E54-E64.
84. Blakey DC, Valcaccia BE, East S, Wright AF, Boyle FT, Springer CJ, Burke PJ, Melton RG, Bagshawe KD: Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug. Cell Biophys (1993) 22(1-3):1-8.
85. Martin J, Stribbling SM, Poon GK, Begent RH, Napier M, Sharma SK, Springer CJ: Antibody-directed enzyme prodrug therapy: Pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother Pharmacol (1997) 40(3):189-201.
86. Marais R, Spooner RA, Light Y, Martin J, Springer CJ: Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res (1996) 56(20):4735-4742.
87. Marais R, Spooner RA, Stribbling SM, Light Y, Martin J, Springer CJ: A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nat Biotechnol (1997) 15(13):1373-1377.
88. Spooner RA, Martin J, Friedlos F, Marais R, Springer CJ: In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug. Cancer Gene Ther (2000) 7(10):1348-1356.
89. Stribbling SM, Friedlos F, Martin J, Davies L, Spooner RA, Marais R, Springer CJ: Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect. Hum Gene Ther (2000) 11(2):285-292.
90. Spooner RA, Friedlos F, Maycroft K, Stribbling SM, Roussel J, Brueggen J, Stolz B, O'Reilly T, Wood J, Matter A, Marais R, Springer CJ: A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs. Br J Cancer (2003) 88(10):1622-1630.
91. Kojima A, Hackett NR, Ohwada A, Crystal RG: In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J Clin Invest (1998) 101(8):1789-1796.
92. Wierdl M, Morton CL, Weeks JK, Danks MK, Harris LC, Potter PM: Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res (2001) 61(13):5078-5082.
93. Meck MM, Wierdl M, Wagner LM, Burger RA, Guichard SM, Krull EJ, Harris LC, Potter PM, Danks MK: A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11. Cancer Res (2001) 61(13):5083-5089.
94. Oosterhoff D, Witlox MA, van Beusechem VW, Haisma HJ, Schaap GR, Bras J, Kruyt FA, Molenaar B, Boven E, Wuisman PI, Pinedo HM, Gerritsen WR: Gene-directed enzyme prodrug therapy for osteosarcoma: Sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2. Mol Cancer Ther (2003) 2(8):765-771.
95. Stubdal H, Perin N, Lemmon M, Holman P, Bauzon M, Potter PM, Danks MK, Fattaey A, Dubensky T, Johnson L: A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38. Cancer Res (2003) 63(20):6900-6908.
96. Wardman P: Indole-3-acetic acids and horseradish peroxidase: A new prodrug/enzyme combination for targeted cancer therapy. Curr Pharm Des (2002) 8(15):1363-1374.
97. de Melo MP, de Lima TM, Pithon-Curi TC, Curi R: The mechanism of indole acetic acid cytotoxicity. Toxicol Lett (2004) 148(1-2):103-111.
98. Kim DS, Jeon SE, Park KC: Oxidation of indole-3-acetic acid by horseradish peroxidase induces apoptosis in G361 human melanoma cells. Cell Signal (2004) 16(1):81-88.
99. Greco O, Folkes LK, Wardman P, Tozer GM, Dachs GU: Development of a novel enzyme/prodrug combination for gene therapy of cancer: Horseradish peroxidase/indole-3-acetic acid. Cancer Gene Ther (2000) 7(11):1414-1420.
100. Greco O, Tozer GM, Dachs GU: Oxic and anoxic enhancement of radiation-mediated toxicity by horseradish peroxidase/indole-3-acetic acid gene therapy. Int J Radiat Biol (2002) 78(3):173-181.
101. Greco O, Marples B, Dachs GU, Williams KJ, Patterson AV, Scott SD: Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Ther (2002) 9(20):1403-1411.
102. Miki K, Xu M, Gupta A, Ba Y, Tan Y, Al-Refaie W, Bouvet M, Makuuchi M, Moossa AR, Hoffman RM: Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. Cancer Res (2001) 61(18):6805-6810.
103. Yamamoto N, Gupta A, Xu M, Miki K, Tsujimoto Y, Tsuchiya H, Tomita K, Moossa AR, Hoffman RM: Methioninase gene therapy with selenomethionine induces apoptosis in Bcl-2-overproducing lung cancer cells. Cancer Gene Ther (2003) 10(6):445-450.
104. Gupta A, Miki K, Xu M, Yamamoto N, Moossa AR, Hoffman RM: Combination efficacy of doxorubicin and adenoviral methioninase gene therapy with prodrug selenomethionine. Anticancer Res (2003) 23(2B):1181-1188.
105. Patterson LH, Murray GI: Tumour cytochrome P450 and drug activation. Curr Pharm Des (2002) 8(15):1335-1347.
106. Moore MJ: Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet (1991) 20(3):194-208.
107. Schwartz PS, Waxman DJ: Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol (2001) 60(6):1268-1279.
108. Wei MX, Tamiya T, Rhee RJ, Breakefield XO, Chiocca EA: Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res (1995) 1(10):1171-1177.
109. Chen L, Yu LJ, Waxman DJ: Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res (1997) 57(21):4830-4837.
110. Huang Z, Raychowdhury MK, Waxman DJ: Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model. Cancer Gene Ther (2000) 7(7):1034-1042.
111. Kan O, Griffiths L, Baban D, Iqball S, Uden M, Spearman H, Slingsby J, Price T, Esapa M, Kingsman S, Kingsman A et al: Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer. Cancer Gene Ther (2001) 8(7):473-482.
112. Schwartz PS, Chen CS, Waxman DJ: Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35. Cancer Res (2002) 62(23):6928-6937,
113. Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA: Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res (1999) 59(16):3861-3865.
114. Carrio M, Visa J, Cascante A, Estivill X, Fillat C: Intratumoral activation of cyclophosphamide by retroviral transfer of the cytochrome P450 2B1 in a pancreatic tumor model. Combination with the HSVtk/GCV system. J Gene Med (2002) 4(2):141-149.
115. Griffiths L, Binley K, Iqball S, Kan O, Maxwell P, Ratcliffe P, Lewis C, Harris A, Kingsman S, Naylor S: The macrophage - a novel system to deliver gene therapy to pathological hypoxia. Gene Ther (2000) 7(3):255-262.
116. Jounaidi Y, Waxman DJ: Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. Cancer Res (2004) 64(1):292-303.
117. Binley K, Askham Z, Martin L, Spearman H, Day D, Kingsman S, Naylor S: Hypoxia-mediated tumour targeting. Gene Ther (2003) 10(7):540-549.
118. Lohr M, Muller P, Karle P, Stange J, Mitzner S, Jesnowski R, Nizze H, Nebe B, Liebe S, Salmons B, Gunzburg WH: Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Ther (1998) 5(8):1070-1078.
119. Karle P, Renner M, Salmons B, Gunzburg WH: Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide. Cancer Gene Ther (2001) 8(3):220-230.
120. Kammertoens T, Gelbmann W, Karle P, Alton K, Saller R, Salmons B, Gunzburg WH, Uckert W: Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine. Cancer Gene Ther (2000) 7(4):629-636.
121. Hejmadi MV, McKeown SR, Friery OP, McIntyre IA, Patterson LH, Hirst DG: DNA damage following combination of radiation with the bioreductive drug AQ4N: Possible selective toxicity to oxic and hypoxic tumour cells. Br J Cancer (1996) 73(4):499-505.
122. McCarthy HO, Yakkundi A, McErlane V, Hughes CM, Keilty G, Murray M, Patterson LH, Hirst DG, McKeown SR, Robson T: Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther (2003) 10(1):40-48.
123. McErlane VM: The anti-tumour effect of AQ4N and its' enhancement using a gene therapy strategy. PhD Thesis, University of Ulster, Coleraine, Northern Ireland (2003).
124. Rainov NG, Dobberstein KU, Sena-Esteves M, Herrlinger U, Kramm CM, Philpot RM, Hilton J, Chiocca EA, Breakefield XO: New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Gene Ther (1998) 9(9):1261-1273.
125. Mohr L, Rainov NG, Mohr UG, Wands JR: Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma. Cancer Gene Ther (2000) 7(7):1008-1014.
126. Frank S, Steffens S, Fischer U, Tlolko A, Rainov NG, Kramm CM: Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: Implications for pharmacogene therapy. Cancer Gene Ther (2002) 9(2):178-188.
127. Hsu H, Rainov NG, Quinones A, Eling DJ, Sakamoto KM, Spear MA: Combined radiation and cytochrome CYP4B1/4-ipomeanol gene therapy using the EGR1 promoter. Anticancer Res (2003) 23(3B):2723-2728.
128. Patterson AV, Williams KJ, Cowen RL, Jaffar M, Telfer BA, Saunders M, Airley R, Honess D, van der Kogel AJ, Wolf CR, Stratford IJ: Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Ther (2002) 9(14):946-954.
129. Cowen RL, Williams KJ, Chinje EC, Jaffar M, Sheppard FC, Telfer BA, Wind NS, Stratford IJ: Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: Reversing tumor radioresistance and effecting cure. Cancer Res (2004) 64(4):1396-1402.
130. Cowen RL, Patterson AV, Telfer BA, Airley RE, Hobbs S, Phillips RM, Jaffar M, Stratford IJ, Williams KJ: Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts. Mol Cancer Ther (2003) 2(9):901-909.
131. Jounaidi Y, Waxman DJ: Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res (2000) 60(14):3761-3769.
132. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res (1986) 46(10):5276-5281.
133. Greco O, Dachs GU: Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives. J Cell Physiol (2001) 187(1):22-36.
134. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chiang Y, McGarrity GJ, Muul LM, Katz D et al: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med (1997) 3(12):1354-1361.
135. Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, Mokhtari K, Diquet B, Salzmann JL, Philippon J: A phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther (1998) 9(17):2595-2604.
136. Shand N, Weber F, Mariani L, Bernstein M, Gianella-Borradori A, Long Z, Sorensen AG, Barbier N: A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther (1999) 10(14):2325-2335.
137. Packer RJ, Raffel C, Villablanca JG, Tonn JC, Burdach SE, Burger K, LaFond D, McComb JG, Cogen PH, Vezina G, Kapcala LP: Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J Neurosurg (2000) 92(2):249-254.
138. Trask TW, Trask RP, Aguilar-Cordova E, Shine HD, Wyde PR, Goodman JC, Hamilton WJ, Rojas-Martinez A, Chen SH, Woo SL, Grossman RG: Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther (2000) 1(2):195-203.
139. Smitt PS, Driesse M, Wolbers J, Kros M, Avezaat C: Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol Ther (2003) 7(6):851-858.
140. Rainov NG: A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther (2000) 11(17):2389-2401.
141. Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M, Hurskainen H, Tyynela K, Turunen M, Vanninen R, Lehtolainen P et al: Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther (2000) 11(16):2197-2205.
142. Sung MW, Yeh HC, Thung SN, Schwartz ME, Mandeli JP, Chen SH, Woo SL: Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: Results of a phase I clinical trial. Mol Ther (2001) 4(3):182-191.
143. Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, Wheeler TM, Thompson TC, Scardino PT: In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial. Hum Gene Ther (1999) 10(7):1239-1249.
144. Miles BJ, Shalev M, Aguilar-Cordova E, Timme TL, Lee HM, Yang G, Adler HL, Kernen K, Pramudji CK, Satoh T, Gdor Y et al: Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther (2001) 12(16):1955-1967.
145. Teh BS, Aguilar-Cordova E, Kernen K, Chou CC, Shalev M, Vlachaki MT, Miles B, Kadmon D, Mai WY, Caillouet J, Davis M et al: Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer - a preliminary report. Int J Radiat Oncol Biol Phys (2001) 51(3):605-613.
146. Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M et al: Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys (2004) 58(5):1520-1529.
147. Alvarez RD, Gomez-Navarro J, Wang M, Barnes MN, Strong TV, Arani RB, Arafat W, Hughes JV, Siegal GP, Curiel DT: Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther (2000) 2(5):524-530.
148. Hasenburg A, Tong XW, Rojas-Martinez A, Nyberg-Hoffman C, Kieback CC, Kaplan A, Kaufman RH, Ramzy I, Aguilar-Cordova E, Kieback DG: Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther (2000) 7(6):839-844.
149. Klatzmann D, Cherin P, Bensimon G, Boyer O, Coutellier A, Charlotte F, Boccaccio C, Salzmann JL, Herson S: A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. Hum Gene Ther (1998) 9(17):2585-2594.
150. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K, Recio A, Knox L, Wilson JM, Albelda SM, Kaiser LR: Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther (1998) 9(7):1083-1092.
151. Pandha HS, Martin LA, Rigg A, Hurst HC, Stamp GW, Sikora K, Lemoine NR: Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of ErbB-2-directed suicide gene expression. J Clin Oncol (1999) 17(7):2180-2189.
152. Freytag SO, Khil M, Stricker H, Peabody J, Menon M, DePeralta-Venturina M, Nafziger D, Pegg J, Paielli D, Brown S, Barton K et al: Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res (2002) 62(17):4968-4976.
153. Freytag SO, Stricker H, Pegg J, Paielli D, Pradhan DG, Peabody J, DePeralta-Venturina M, Xia X, Brown S, Lu M, Kim JH: Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res (2003) 63(21):7497-7506.
154. Chung-Faye G, Palmer D, Anderson D, Clark J, Downes M, Baddeley J, Hussain S, Murray PI, Searle P, Seymour L, Harris PA et al: Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: A phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res (2001) 7(9):2662-2668.
155. Palmer DH, Mautner V, Mirza D, Oliff S, Gerritsen W, van der Sijp JR, Hubscher S, Reynolds G, Bonney S, Rajaratnam R, Hull D et al: Virus-directed enzyme prodrug therapy: Intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol (2004) 22(9):1546-1552.
156. James ND, Young JG, Patel P, Leung H, Searle P, Mautner V, Ellis J, Doherty A, Wallace M, Young L: A biodistribution study of adenovirus-delivered nitroreductase (Ad-NTR) in patients with operable prostate cancer. Proc Am Soc Clin Oncol (2003):Abs 818.
157. Lohr M, Kroger JC, Hoffmeyer A, Freund M, Hain J, Holle A, Knofel WT, Liebe S, Nizze H, Renner M, Saller R et al: Safety, feasibility and clinical benefit of localized chemotherapy using microencapsulated cells for inoperable pancreatic carcinoma in a phase I/II trial. Cancer Ther (2003) 1:121-131.
158. Floeth FW, Shand N, Bojar H, Prisack HB, Felsberg J, Neuen-Jacob E, Aulich A, Burger KJ, Bock WJ, Weber F: Local inflammation and devascularization - in vivo mechanisms of the "bystander effect" in VPC-mediated HSV-tk/GCV gene therapy for human malignant glioma. Cancer Gene Ther (2001) 8(11):843-851.